1. Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database
- Author
-
Vít Procházka, Jiri Mayer, Jan Pirnos, David Belada, Zbynek Bortlicek, Vit Campr, Marek Trneny, Heidi Mocikova, Natasa Kopalova, Jitka Hamouzova, Robert Pytlik, Andrea Janíková, Samuel Vokurka, Juraj Duras, and Katerina Benesova
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Databases, Factual ,First line ,Follicular lymphoma ,Antineoplastic Agents ,Drug Administration Schedule ,Maintenance Chemotherapy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Retrospective analysis ,Humans ,Stage (cooking) ,Lymphoma, Follicular ,Aged ,Czech Republic ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Time to progression ,business.industry ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,3. Good health ,Lymphoma ,First line treatment ,Treatment Outcome ,030220 oncology & carcinogenesis ,Immunology ,Disease Progression ,Female ,Rituximab ,business ,030215 immunology ,medicine.drug - Abstract
Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM given for up to 2 years vs observation in 319 untreated FL patients (stage II-IV; grade 1-3A) responding to RCHOP induction and a comparison of two different RM schedules (RM8=eight doses given every 3 months and RM12=12 doses given every 2 months). A total of 183 patients received RM and 136 patients were observed; 5-year PFS was better in the RM arm, 74.1% vs 52.3% (p
- Published
- 2015
- Full Text
- View/download PDF